← Eichor
Study identifier: NCT06277791 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

The Combination of Adebrelimab and TP Regimen for Neoadjuvant Therapy in Patients With Stage IVB Oral Squamous Cell Carcinoma

Condition: Clinical IVb Stage Oral Squamous Cell Carcinomas Patients  ·  Sponsor: Hospital of Stomatology, Wuhan University

PhasePhase 2
Planned participants35
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

The goal of this \[type of study:clinical trial\] is to \[learn about\] in \[Clinical IVB stage oral squamous cell carcinoma patients\]. The main question it aims to answer are: • \[Observing the effectiveness and safety of the combination of Adebrelimab and TP regimen in neoadjuvant therapy for clinical IVB stage oral squamous cell carcinoma patients\] Participants will \[Received treatment with Adebrelimab combined with TP regimen, followed by surgery after 2 cycles of neoadjuvant therapy. After surgery, radiotherapy and chemotherapy combined with immunotherapy were chosen based on the patient\'s condition, with a total follow-up of two years.\].

This description comes directly from the study's public registry record.

Talk to the study team

JJia Associate Professor  ·  +8613277924848  ·  junjia@whu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

School of Stomatology Wuhan UniversityHubei, Wuhan, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06277791